Patents Issued in January 14, 2020
  • Patent number: 10532016
    Abstract: Disclosed herein are zinc-amino acid-tripolyphosphate complexes, oral care and personal care compositions comprising zinc-amino acid-tripolyphosphate complexes, and methods of making and using the same.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: January 14, 2020
    Assignee: Colgate-Palmolive Company
    Inventors: Zhigang Hao, Dennis Zhang, Donghui Wu, Ravi Subramanyam, Chi-Yuan Cheng, Long Pan, Stanislav Jaracz
  • Patent number: 10532017
    Abstract: The present disclosure relates to antioxidant compositions comprising a high amount of stabilized neohesperidin dihydrochalcone. The antioxidant compositions may further include additional antioxidants, such as ferulic acid, and tocopherols. The compositions include at least 20 wt. % of one or more water-soluble solvents, such as propanediol, which contribute to the surprising solubility and stability of the compositions. The antioxidant properties of the compositions make them particularly effective for treating and protecting the skin. For example, the compositions are useful for protecting the skin from environmental insult.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 14, 2020
    Assignee: L'OREAL
    Inventors: Lisa Yarhyna Lema, Valerie Robert, Jodi Goldberg, Geoffrey Genesky
  • Patent number: 10532018
    Abstract: A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 14, 2020
    Assignee: ANPEP INC.
    Inventors: Sang Moon Kang, Seock Yeon Hwang, Mi Hye Lim, Chung Park, Eun Jin Shin, Kee-young Lee, Un Kyu Park, Hyun Ji Lim, Dong Hyun Yang, Sang Joo Cha
  • Patent number: 10532019
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: January 14, 2020
    Assignee: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Patent number: 10532020
    Abstract: The present embodiments relate to a nail coating having a major advantage in that it enables a nail coating to adhere to a natural nail or uncoated nail for long wear periods without adhesion loss or other signs of breakdown of the coating. Nail topcoats with improved abrasion resistance are also disclosed. Adhesion of a composition for nail coatings be improved by addition of a polyhedral oligomeric silsesquioxane (POSS). Nail coating compositions that benefit from the addition of a POSS include enamels, reactive composition such as those containing acrylates, solventless compositions and water-based compositions.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: January 14, 2020
    Assignee: Revlon Consumer Products Corporation
    Inventors: David Valia, Jamie Ellis
  • Patent number: 10532021
    Abstract: The present invention relates to a non-colouring composition for treating keratin fibres comprising an aqueous dispersion of particles of hybrid hydrophobic acrylic film-forming polymer and a linear block silicone copolymer, and also to a method for treating keratin fibres using such a composition. The composition makes it possible to obtain a coating which is persistent towards shampooing operations, which leaves the treated fibres individualized, with an improved cosmetic feel and a provision of mass and volume.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: January 14, 2020
    Assignee: L'OREAL
    Inventor: Karen Teboul
  • Patent number: 10532022
    Abstract: The present invention relates to processes for producing treated olive mill process water (OMPW). In some exemplary embodiments, the treated OMPW is used in the preparation/production of body care products.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: January 14, 2020
    Assignees: The United States of America, as represented by The Secretary of Agriculture, McEvoy of Marin, LLC
    Inventors: Rebecca R Milczarek, Jeffrey A Creque, John Bailey, Ellen Roggemann
  • Patent number: 10532023
    Abstract: Disclosed is a Japanese camellia extract, obtained by extracting Camellia japonica flowers by way of a fatty substance or fatty substance mixture, and to a cosmetic composition including one such extract that has, in particular, a skin-moisturizing effect.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 14, 2020
    Assignee: CHANEL PARFUMS BEAUTE
    Inventors: Anne Rossignol-Castera, Annabelle L'Hermitte, Gaelle Gendronneau, Serge Holderith, Yannick Maestro
  • Patent number: 10532024
    Abstract: Compositions for suppressing sebum production in skin (e.g., seborrheic skin), and minimizing glycation in skin (e.g., mature skin) with enhanced UV absorptive properties are described. In particular, the present invention relates to a composition containing a skin benefit agent that includes Lithospermum erythrorhizon. Also, methods of suppressing sebum production in skin (e.g., seborrheic skin) and minimizing glycation in skin (e.g., mature skin) by applying a composition to the skin, wherein the composition comprises an effective amount of a derivative of Lithospermum erythrorhizon are also described.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: January 14, 2020
    Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC
    Inventors: Rodney A. Velliquette, Kelly M. Glynn, Ernest H. Brumbaugh, Penelope M. Anderson, John F. Rebhun, Stephen R. Missler, Arun Rajgopal
  • Patent number: 10532025
    Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: January 14, 2020
    Assignee: Bayer Oy
    Inventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
  • Patent number: 10532026
    Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 14, 2020
    Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Yamamura, Ayaka Yamamuro, Emi Izukura, Moto Kimura, Tomohiro Otsuka
  • Patent number: 10532027
    Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: January 14, 2020
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
  • Patent number: 10532028
    Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of providing a mixture comprising an organic material in a blend of a solvent and non-solvent for the organic material, distributing the mixture into either droplets or granules, and evaporating the solvent and non-solvent mixture to form particles having an average size of from about 0.5 ?m to about 5000 ?m.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: January 14, 2020
    Assignee: ISP INVESTMENTS LLC
    Inventor: John Alfred Doney
  • Patent number: 10532029
    Abstract: Provided are an alkyl cellulose excellent in formability when added even in a small amount and not causing marked delay in disintegration; a solid preparation comprising it; and a method for producing the solid preparation. More specifically, provided are an alkyl cellulose for use in tableting, the alkyl cellulose having a specific surface area of from 0.5 to 10.0 m2/g as measured by BET method and a solid preparation comprising the alkyl cellulose. Also provided is a method for producing the alkyl cellulose, comprising the steps of: bringing pulp into contact with an alkali metal hydroxide solution to obtain alkali cellulose, reacting the alkali cellulose with an etherifying agent to obtain a first alkyl cellulose, pulverizing the first alkyl cellulose, and depolymerizing the pulverized first alkyl cellulose through hydrolysis with an acid catalyst or through oxidative decomposition with an oxidant to obtain a second alkyl cellulose.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: January 14, 2020
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Takuya Yokosawa, Naosuke Maruyama
  • Patent number: 10532030
    Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: January 14, 2020
    Assignee: LOCL PHARMA, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 10532031
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 14, 2020
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
  • Patent number: 10532032
    Abstract: The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 14, 2020
    Assignee: TAKEDA AS
    Inventors: Wolfgang Schoenhofer, Pernille Dybendal Pedersen, Poul Bertelsen, Henrik Braender, Ingrid Blanka, Henrik Neuschaefer Larsen
  • Patent number: 10532033
    Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: January 14, 2020
    Assignee: LTS LOHMANN Therapie-Systeme AG
    Inventor: Walter Müller
  • Patent number: 10532034
    Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: January 14, 2020
    Assignee: Cornell University
    Inventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
  • Patent number: 10532035
    Abstract: Methods herein are described for improvement in visual function by administering macular carotenoid compositions containing an effective daily dose, to a subject in need thereof. More particularly, methods herein are described and include use of the compositions herein by identifying a subject in need thereof, administering a daily dose of lutein and/or zeaxanthin isomers, comprised of meso-zeaxanthin and R,R zeaxanthin, alone or in combination thereof, the composition also including at least one food grade excipient, and evaluating visual performance. The subject is exposed to light of variable wavelengths and intensity and is suffering from visual fatigue. The composition improves contrast sensitivity, glare performance, photo stress recovery, and/or macular pigment optical density, and thus alleviates visual fatigue. The composition is safe for human and other animals for consumption and can be used for improvement in visual health in the subject, when administered in an effective amount.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 14, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Vijaya Juturu, Khadija Ghanam, Lynda Doyle
  • Patent number: 10532036
    Abstract: A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: January 14, 2020
    Assignee: AFT Pharmaceuticals Limited
    Inventor: Hartley Campbell Atkinson
  • Patent number: 10532037
    Abstract: A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 14, 2020
    Assignee: ARSTAT, Inc.
    Inventor: Arkady Rubin
  • Patent number: 10532038
    Abstract: The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 14, 2020
    Assignees: FUNDACÍON CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC), HOSPITAL CLÍNIC DE BARCELONA
    Inventors: Borja Ibáñez Cabeza, Ana García-Álvarez, Valentín Fuster Carulla
  • Patent number: 10532039
    Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: January 14, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10532040
    Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: January 14, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim
  • Patent number: 10532041
    Abstract: A method is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity. A composition made by this method is also disclosed.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 14, 2020
    Assignee: Vectura Limited
    Inventor: Fergus Manford
  • Patent number: 10532042
    Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 14, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • Patent number: 10532043
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: January 14, 2020
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Patent number: 10532044
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: January 14, 2020
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
  • Patent number: 10532045
    Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 14, 2020
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard
  • Patent number: 10532046
    Abstract: The present disclosure relates to compositions that are useful in the delivery of various materials. In particular, the compositions comprise a suspension wherein an internal phase material is surrounded by an external phase material. The internal phase specifically can be a hydrophilic material, and the external phase specifically can be a hydrophobic material. The materials are combined so that the internal phase is substantially encapsulated by the external phase such that release can be controlled in relation to osmotic pressure differentials. The suspension can be combined with a carrier, and various systems and products can be formed with the suspension and optional carrier, such as oral strips, spray delivery systems, smokeless tobacco products, aerosol delivery devices, cigarettes, and packaging.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: January 14, 2020
    Assignee: Niconovum USA, Inc.
    Inventors: James William Rogers, Michael F. Davis, Percy D. Phillips, Karen V. Taluskie, Stephen Benson Sears, Ercilia Hernandez Garcia
  • Patent number: 10532047
    Abstract: The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: January 14, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventor: George P. Luke
  • Patent number: 10532048
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 14, 2020
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 10532049
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 14, 2020
    Assignee: Pharmaceutical Industries Limited
    Inventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
  • Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • Patent number: 10532051
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 14, 2020
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
  • Patent number: 10532052
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: January 14, 2020
    Assignee: Merck Patent GmbH
    Inventors: Friedhelm Bladt, Manja Friese-Hamim
  • Patent number: 10532053
    Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 14, 2020
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Lijuan Chen, Chaofeng Long, Xiaoxin Chen, Zhuowei Liu, Haoyu Ye, Chenshi Xie
  • Patent number: 10532054
    Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 14, 2020
    Assignee: Resverlogix Corp.
    Inventor: Henrik C. Hansen
  • Patent number: 10532056
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: January 14, 2020
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Patent number: 10532057
    Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 14, 2020
    Assignee: Prexton Therapeutics SA
    Inventors: Delphine Charvin, François Conquet
  • Patent number: 10532058
    Abstract: The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7-ACA).
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: January 14, 2020
    Assignee: Sandoz AG
    Inventors: Michael Fischer, Wolfgang Felzmann, Ronny Huetz, Martin Langner, Birgit Endl
  • Patent number: 10532059
    Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: January 14, 2020
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
  • Patent number: 10532060
    Abstract: The present invention relates to a serum LDL cholesterol lowering edible product containing plant sterol ester and/or plant stanol ester, and especially to a dietary supplement product.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: January 14, 2020
    Assignee: Raisio Nutrition Ltd.
    Inventors: Ingmar Wester, Paivi Kuusisto, Jouni Reijo Kalevi Niemela, Tuula Forbom, Kurt I. Draget, Andrzej Siwek, Kamilla Lundhaug, Jan Erik Olsen
  • Patent number: 10532061
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 10532063
    Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: January 14, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Steven Ray Gilbert, Edward Paul Fitch, V, Derrick Ho, Daniel Jerome White, Jr., Adam Michael Tunis
  • Patent number: 10532064
    Abstract: Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a V?9V?2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human V?9V?2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC).
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 14, 2020
    Assignee: The University of Hong Kong
    Inventors: Wenwei Tu, Zheng Xiang, Yinping Liu
  • Patent number: 10532065
    Abstract: The novel bisphosphonic acid ester derivatives represented by the following formula (1): Y—Cy—(NH)m—(CH2)n—C(X)(PO(OR1)(OR2))2??(1) wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 14, 2020
    Assignee: NAGASAKI UNIVERSITY
    Inventors: Yoshimasa Tanaka, Kenji Matsumoto, Kosuke Hayashi, Yuki Sakai, Nagahiro Minato
  • Patent number: 10532066
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: January 14, 2020
    Assignee: National Jewish Health
    Inventors: Dennis R. Voelker, Mari Numata-Nakamura
  • Patent number: 10532067
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: January 14, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl